Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rainbow BioSciences (RBCC) has signed a letter of intent (LOI) to progress Amarantus BioSciences’s Parkinson’s disease program, including an early detection diagnostic blood test and a disease-modifying protein drug candidate.
Subscribe to our email newsletter
The companies have agreed to a 60-day option period whereby RBCC and Amarantus will negotiate for RBCC to provide funding and knowledge toward the development and marketing of one or more of Amarantus’ projects.
Amarantus owns the rights to MANF, a potential cure for Parkinson’s, which prevents a type of cell death called apoptosis.
Amarantus also owns the license to a diagnostic platform called NuroPro for Parkinson’s that allows neurologists to diagnose and track the progression of Parkinson’s disease in patients.
RBCC anticipates that the consummation of a transaction contemplated in this LOI would position RBCC to capitalize on that growth.